AI assistant
REPLIGEN CORP — Director's Dealing 2014
Mar 3, 2014
30826_dirs_2014-03-03_6cae9d13-87ce-4aa0-8567-31e0718eeb6f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: REPLIGEN CORP (RGEN)
CIK: 0000730272
Period of Report: 2014-02-27
Reporting Person: WITT DANIEL P (Senior Vice President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-02-27 | Common Stock | A | 6182 | — | Acquired | 53891 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2014-02-27 | Stock Option (Right to Buy) | $15.91 | A | 11842 | Acquired | 2024-02-27 | Common Stock (11842) | Direct |
Footnotes
F1: Mr. Witt was awarded 6,182 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. 2,060 Restricted Stock Units vest on 2/27/2015. 2,061 Restricted Stock Units vest on each of 2/27/2016 and 2/27/2017. The Restricted Stock Units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
F2: 3,947 shares vest and become exercisable on each of 2/27/2015 and 2/27/2016. 3,948 shares vest and become exercisable on 2/27/2017.